Boston Scientific Corporation $BSX Stake Boosted by Bowen Hanes & Co. Inc.

Bowen Hanes & Co. Inc. increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 414,280 shares of the medical equipment provider’s stock after buying an additional 8,220 shares during the quarter. Bowen Hanes & Co. Inc.’s holdings in Boston Scientific were worth $44,498,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the 1st quarter worth about $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific in the first quarter worth approximately $27,000. Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific in the second quarter worth approximately $37,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $96.77 on Friday. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company has a market cap of $143.46 billion, a P/E ratio of 51.75, a P/E/G ratio of 2.02 and a beta of 0.58. The business’s 50 day moving average is $98.97 and its two-hundred day moving average is $102.38. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent research reports. Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. The Goldman Sachs Group reissued a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $123.77.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 175,782 shares of company stock worth $17,742,314. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.